Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors

By The Science Advisory Board staff writers

July 6, 2020 -- Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.

The companies previously announced that they identified four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). These have been synthesized and are in the process of being tested in biological assays.

Now, the companies have jointly developed a new in silico library of analog compounds, based on the main protease scaffold compound, that will be evaluated through additional in silico screening to choose which additional compounds may be synthesized and evaluated in biological assays.

Complete screening results are expected to be available within weeks.

Getting to the heart of SARS-CoV-2 protease; a main drug target
Getting to the heart of SARS-CoV-2 protease; a main drug target
Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...
Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter